Nyrada (ASX:NYR) Debt-to-Revenue : N/A (As of Dec. 2023)

View and export this data going back to 2020. Start your Free Trial

What is Nyrada Debt-to-Revenue?

Debt-to-Revenue measures a company's ability to pay off its debt.

Nyrada's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was A$0.00 Mil. Nyrada's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was A$0.00 Mil. Nyrada's annualized Revenue for the quarter that ended in Dec. 2023 was A$0.00 Mil.

Nyrada Debt-to-Revenue Historical Data

The historical data trend for Nyrada's Debt-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Nyrada Debt-to-Revenue Chart

Nyrada Annual Data

Trend

Jun19

Jun20

Jun21

Jun22

Jun23

Debt-to-Revenue

N/A

Nyrada Semi-Annual Data
	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Debt-to-Revenue	Get a 7-Day Free Trial			N/A	N/A	N/A	N/A	N/A

Competitive Comparison of Nyrada's Debt-to-Revenue

For the Biotechnology subindustry, Nyrada's Debt-to-Revenue, along with its competitors' market caps and Debt-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Nyrada's Debt-to-Revenue Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Nyrada's Debt-to-Revenue distribution charts can be found below:

* The bar in red indicates where Nyrada's Debt-to-Revenue falls into.

Nyrada Debt-to-Revenue Calculation

Debt-to-Revenue measures a company's ability to pay off its debt.

Nyrada's Debt-to-Revenue for the fiscal year that ended in Jun. 2023 is calculated as

Debt-to-Revenue	=	Total Debt			/	Revenue
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Revenue
	=	(0	+	0)	/	N/A
	=	N/A

Nyrada's annualized Debt-to-Revenue for the quarter that ended in Dec. 2023 is calculated as

Debt-to-Revenue	=	Total Debt			/	Revenue
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Revenue
	=	(0	+	0)	/	0
	=	N/A

In the calculation of annual Debt-to-Revenue, the Revenue of the last fiscal year is used. In calculating the annualized quarterly data, the Revenue data used here is two times the quarterly (Dec. 2023) Revenue data.

Nyrada Debt-to-Revenue Related Terms

Thank you for viewing the detailed overview of Nyrada's Debt-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

Nyrada (ASX:NYR) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Nyrada Inc (ASX:NYR) » Definitions » Debt-to-Revenue

Comparable Companies

Traded in Other Exchanges

N/A

Address

828 Pacific Highway, Suite 2, Level 3, Gordon, NSW, AUS, 2072

Website

https://www.nyrada.com

Nyrada Inc is a preclinical-stage, drug discovery, and development company, specializing in novel small-molecule drugs to treat cardiovascular and neurological diseases. The company's two programs center on cholesterol-lowering and brain injury, each targeting market sectors of notable size and unmet clinical needs. The programs are focused on developing an oral, small molecule cholesterol-lowering drug, and a drug to treat secondary brain damage following a stroke or traumatic brain injury.

Nyrada (ASX:NYR) Headlines

No Headlines